|
EP0737750B1
(en)
|
1989-03-21 |
2003-05-14 |
Vical, Inc. |
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
EP1021548A1
(en)
|
1997-10-07 |
2000-07-26 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing rna in animal cells
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
EP2286792A1
(en)
|
1999-02-26 |
2011-02-23 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
DE69943068D1
(de)
|
1999-09-09 |
2011-02-03 |
Curevac Gmbh |
Transfer von mRNA unter Verwendung von polykationischen Verbindungen
|
|
WO2001021810A1
(en)
|
1999-09-17 |
2001-03-29 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
GB2367249B
(en)
*
|
2000-07-18 |
2004-06-23 |
Robert Patrick Hart |
Underwater breathing device
|
|
ATE346947T1
(de)
|
2000-07-21 |
2006-12-15 |
Glaxo Group Ltd |
Kodon-optimierte papillomavirussequenzen
|
|
EP1383556B9
(de)
|
2001-04-21 |
2008-03-19 |
Curevac GmbH |
INJEKTIONSGERÄT FÜR mRNA APPLIKATION
|
|
EP1903054A3
(de)
|
2001-06-05 |
2008-07-23 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
CA2480775C
(en)
|
2002-04-04 |
2016-05-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory g,u-containing oligoribonucleotides
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
AU2003301148A1
(en)
|
2002-12-23 |
2004-07-22 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
|
EP1651666B1
(en)
|
2003-07-11 |
2009-05-27 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
JP2010507361A
(ja)
|
2006-07-31 |
2010-03-11 |
キュアバック ゲーエムベーハー |
具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
|
|
CN101148661B
(zh)
*
|
2006-09-18 |
2013-01-02 |
中国医学科学院基础医学研究所 |
人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US8748127B2
(en)
*
|
2007-05-29 |
2014-06-10 |
Xiamen University |
Truncated L1 protein of human papillomavirus type 6
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
CA2917512C
(en)
|
2007-10-12 |
2025-08-05 |
President And Fellows Of Harvard College |
VACCINE NANOTECHNOLOGY
|
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
|
EA020954B1
(ru)
|
2008-06-16 |
2015-03-31 |
Бинд Терапьютикс, Инк. |
Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
EP4241767B1
(en)
|
2008-11-10 |
2024-10-23 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
WO2010057203A2
(en)
|
2008-11-17 |
2010-05-20 |
The Board Of Regents Of The University Of Texas System |
Hdl particles for delivery of nucleic acids
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
RU2016137258A
(ru)
|
2009-04-01 |
2018-12-13 |
Юниверсити Оф Майами |
Композиции вакцин и способы их применения
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
|
EP3449910A1
(en)
|
2010-07-06 |
2019-03-06 |
GlaxoSmithKline Biologicals S.A. |
Cationic oil-in-water emulsions
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
US8968746B2
(en)
|
2010-07-30 |
2015-03-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
BR112013004879A2
(pt)
|
2010-08-31 |
2018-04-24 |
Novartis Ag |
lipossomas pequenos para entrega de rna que codifica imunogénio
|
|
WO2012031043A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
TR201908635T4
(tr)
|
2010-08-31 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012099805A2
(en)
|
2011-01-19 |
2012-07-26 |
Ocean Nanotech, Llc |
Nanoparticle based immunological stimulation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
CN103687957A
(zh)
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
|
CN107115314B
(zh)
|
2011-06-02 |
2022-04-29 |
加利福尼亚大学董事会 |
膜包封的纳米颗粒及使用方法
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
RU2649133C2
(ru)
|
2011-07-06 |
2018-03-29 |
Новартис Аг |
Катионные эмульсии масло-в-воде
|
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
EP4014966A1
(en)
*
|
2011-07-06 |
2022-06-22 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
CN103930547A
(zh)
|
2011-09-02 |
2014-07-16 |
诺华股份有限公司 |
用于治疗hsf1相关疾病的有机组合物
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2013039861A2
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
*
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US20140271829A1
(en)
|
2011-10-11 |
2014-09-18 |
Anders Lilja |
Recombinant self-replicating polycistronic rna molecules
|
|
AU2012323937A1
(en)
|
2011-10-14 |
2014-06-05 |
Stc.Unm |
Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
|
|
ES2745373T3
(es)
|
2011-10-18 |
2020-03-02 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
ES2719598T3
(es)
|
2012-05-25 |
2019-07-11 |
Curevac Ag |
Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
|
|
WO2013185069A1
(en)
*
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
WO2014071963A1
(en)
|
2012-11-09 |
2014-05-15 |
Biontech Ag |
Method for cellular rna expression
|
|
JP6353846B2
(ja)
|
2012-11-09 |
2018-07-04 |
バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ |
細胞のｒｎａ発現方法
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
JP2016513115A
(ja)
*
|
2013-02-21 |
2016-05-12 |
チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド |
ワクチン組成物
|
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
ES2882110T3
(es)
*
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
EP4614148A3
(en)
*
|
2013-03-15 |
2025-12-17 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
US10125172B2
(en)
|
2013-07-25 |
2018-11-13 |
Calder Biosciences Inc. |
Conformationally stabilized RSV pre-fusion F proteins
|
|
AU2014310933B2
(en)
|
2013-08-21 |
2020-05-14 |
CureVac SE |
Method for increasing expression of RNA-encoded proteins
|
|
CA2915728A1
(en)
|
2013-08-21 |
2015-02-26 |
Thomas Kramps |
Respiratory syncytial virus (rsv) vaccine
|
|
WO2015130584A2
(en)
*
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
US11571472B2
(en)
|
2014-06-13 |
2023-02-07 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
|
EP3169783A4
(en)
|
2014-07-17 |
2018-10-03 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
JP2018526321A
(ja)
*
|
2015-04-27 |
2018-09-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
CN115197965A
(zh)
*
|
2015-06-10 |
2022-10-18 |
霍欧奇帕生物科技有限公司 |
Hpv疫苗
|
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
AU2016342048B2
(en)
|
2015-10-22 |
2022-09-08 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
TN2018000154A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Respiratory syncytial virus vaccine
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
CN108430456B
(zh)
|
2015-10-22 |
2022-01-18 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CA3007955A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Lipid nanoparticles for delivery of therapeutic agents
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
US12123030B2
(en)
|
2016-05-18 |
2024-10-22 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
MA45053A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
JP6983455B2
(ja)
|
2016-09-14 |
2021-12-17 |
モデルナティーエックス， インコーポレイテッド |
高純度ｒｎａ組成物及びその調製のための方法
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP3532070A1
(en)
|
2016-10-26 |
2019-09-04 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
|
MX2019004913A
(es)
|
2016-10-26 |
2019-09-16 |
Curevac Ag |
Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
RU2768829C2
(ru)
|
2017-02-01 |
2022-03-24 |
МОДЕРНАТиЭкс, ИНК. |
Противораковые рнк-вакцины
|
|
US20200032274A1
(en)
|
2017-02-01 |
2020-01-30 |
Moderna TX, Inc. |
Polynucleotide secondary structure
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018200737A1
(en)
|
2017-04-26 |
2018-11-01 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|